QCM
KROS icon

Quantinno Capital Management’s Keros Therapeutics KROS Stock Holding History

Quantinno Capital Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$289K Buy
26,971
+3,212
+14% +$35.8K ﹤0.01% 3218
2026
Q1 		$262K Buy
23,759
+2,639
+12% +$40.8K ﹤0.01% 3103
2025
Q4 		$430K Sell
21,120
-11
-0.1% -$193 ﹤0.01% 2567
2025
Q3 		$334K Buy
+21,131
New +$312K ﹤0.01% 2370

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Quantinno Capital Management's KROS Position: Q2 2026 in Review

Quantinno Capital Management increased its Keros Therapeutics (KROS) stake by 14% in Q2 2026, buying an estimated $35.8K and bringing the position to 26,971 shares worth $289K. The position accounts for ﹤0.01% of the portfolio, ranked #3218.

Quantinno Capital Management first reported a position in KROS in Q3 2025 and has held it in 4 quarters since. The position peaked at $430K in Q4 2025. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Quantinno Capital Management held 26,971 shares of Keros Therapeutics worth $289K as of Q2 2026.
  • Quantinno Capital Management bought 3,212 Keros Therapeutics shares in Q2 2026, an estimated $35.8K.
  • Keros Therapeutics made up ﹤0.01% of Quantinno Capital Management's portfolio in Q2 2026, its #3218 holding.
  • Quantinno Capital Management first reported a position in Keros Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Quantinno Capital Management's Keros Therapeutics position peaked at $430K in Q4 2025.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Quantinno Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.